Table 1.
Baseline characteristics of participants started on isoniazid preventive therapy in the REMEMBER trial (N=426)
| Characteristics | n (%) or median (IQR)* |
|---|---|
| Age (years) | 35 (30–42) |
| Sex | |
| Male | 226 (53%) |
| Female | 200 (47%) |
| Race | |
| Black African or black of African origin | 388 (91%) |
| Other | 38 (9%) |
| Country | |
| Malawi | 98 (23%) |
| South Africa | 90 (21%) |
| Kenya | 75 (18%) |
| Haiti | 56 (13%) |
| Zimbabwe | 27 (6%) |
| Uganda | 24 (6%) |
| Peru | 19 (4%) |
| Zambia | 19 (4%) |
| India | 12 (3%) |
| Brazil | 6 (1%) |
| Pretreatment AST/ALT† | |
| Normal | 327 (77%) |
| Raised | 99 (23%) |
| Hepatitis B surface antigen‡ | |
| Negative | 384 (94%) |
| Positive | 26 (6%) |
| APRI score§ | |
| <=1.5 | 412 (97%) |
| >1.5 | 12 (3%) |
| Karnofsky Score | |
| 80–100 | 371 (87%) |
| 0–70 | 55 (13%) |
| CD4 cell count (cells per μL) | 19.0 (9–33) |
| Hemoglobin (g/dL) | 11.3 (10.2–12.6) |
| HIV-1 RNA (log10 copies per mL) | 5.3 (4·9–5·7) |
| Hospital admission within the past 30 days | 23 (5%) |
| Body-mass index <18·5 kg/m2 | 128 (30%) |
| Alcohol intake | |
| Never | 214 (50%) |
| Takes alcohol | 33 (8%) |
| No answer | 179 (42%) |
*
IQR = Interquartile range
†
Raised pretreatment AST/ALT defined as AST and/or ALT elevations at ≥1.25× ULN and <2.5×ULN at study entry.
‡
16 values were missing
§
2 values were missing